Advanced Blood-Brain Barrier Drug Delivery

Edited by
January 2023
496 pages
  • ISBN978-3-0365-6417-3 (Hardback)
  • ISBN978-3-0365-6416-6 (PDF)

This book is a reprint of the Special Issue Advanced Blood-Brain Barrier Drug Delivery that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology

Advanced Blood-Brain Barrier Drug Delivery is a reprint with a summary editorial, followed by 16 chapters that cover five areas of brain drug delivery, including receptor-mediated transport (RMT), carrier-mediated transport (CMT), active efflux transport (AET), Trojan horse lipid nanoparticles (LNP), and in vivo methods for measurement of drug transport across the blood–brain barrier (BBB).

  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
blood–brain barrier (BBB); brain drug delivery; prodrugs; solute carriers (SLCs); lysosomal storage disease; neuronopathic mucopolysaccharidosis; blood–brain barrier; neurodegeneration; enzyme replacement therapy; receptor-mediated transcytosis; transferrin receptor; insulin receptor; blood–brain barrier; endothelium; receptor-mediated transport; carrier-mediated transport; genetic engineering; IgG fusion proteins; nanoparticles; liposomes; TrkB; agonist antibody; variable new antigen receptor (VNAR); neuroprotection; transferrin receptor 1 (TfR1); blood-brain barrier (BBB); 6-OHDA; Parkinson’s disease; bispecific antibody; blood-brain barrier (BBB); alpha-synuclein (αSYN); Parkinson’s disease (PD); immunotherapy; monoclonal antibody; transferrin receptor (TfR); receptor-mediated transcytosis (RMT); blood–brain barrier; receptor-mediated transcytosis; single domains antibody; IGF1R; neurotensin; blood–brain barrier; protein-based therapy; monoclonal antibody; insulin receptor; transferrin receptor; lysosomal storage disorders; fusion proteins; Parkinson’s disease; Alzheimer’s disease; neurotrophic factors; decoy receptors; ATP-binding cassette transporters; blood–brain barrier; drug delivery; ischemic stroke; SLC transporters; lipid nanoparticle; ssPalm; mRNA transfection; blood–brain barrier; hCMEC/D3 cells; cell toxicity; SWATH-MS; translation; chaperonin-containing TCP-1; proton-coupled organic cation antiporter; blood–brain barrier; photo-affinity labeling; proteomics; SWATH-MS (sequential window acquisition of all theoretical-mass spectra); pharmacokinetics; blood–brain barrier; compartmental models; physiologically based PK models; blood-brain barrier; brain drug delivery; receptor-mediated transcytosis; antibody; cavernous sinus; blood–brain barrier; BBB–peptide shuttle; brain delivery; solute carrier (SLC) transporters; blood–brain barrier (BBB); amyotrophic lateral sclerosis (ALS); NSC-34 cell lines; taurine transporter (Taut); large amino acid transporter 1 (LAT1); monocarboxylate transporters (MCTs); organic cation transporters (OCTNs); choline transporter-like protein-1 (CTL1); Alzheimer’s disease; transferrin receptor; TNF-α inhibitor; blood–brain barrier; molecular Trojan horse; antibody; blood–brain barrier; endosomal; liposome; nanoparticle; targeting; transferrin; n/a